Share

March 2023; 10 (2) Diagnostic & Treatment ChallengesOpen Access

MOG Antibody–Associated Disease and Thymic Hyperplasia

From the National Multiple Sclerosis Society Case Conference Proceedings

Brigitte Hurtubise, Elliot M. Frohman, Steven Galetta, Laura J. Balcer, Teresa C. Frohman, Robert P. Lisak, Scott D. Newsome, Jennifer S. Graves, Scott S. Zamvil, Lilyana Amezcua
First published December 14, 2022, DOI: https://doi.org/10.1212/NXI.0000000000200077
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
645

Share

Article Information

vol. 10 no. 2 e200077
DOI: 
https://doi.org/10.1212/NXI.0000000000200077
PubMed: 
36517233
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received September 28, 2022
  • Accepted in final form October 26, 2022
  • First Published December 14, 2022.
Copyright & Usage: 
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Brigitte Hurtubise, MD,
    2. Elliot M. Frohman, MD, PhD,
    3. Steven Galetta, MD,
    4. Laura J. Balcer, MD,
    5. Teresa C. Frohman, MPAS, PA-C,
    6. Robert P. Lisak, MD,
    7. Scott D. Newsome, DO,
    8. Jennifer S. Graves, MD, PhD, MAS,
    9. Scott S. Zamvil, MD, PhD and
    10. Lilyana Amezcua, MD, MS
  1. Brigitte Hurtubise, MD,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Elliot M. Frohman, MD, PhD,
    3. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Genzyme-Speaker feesNovartis-Speaker feesAlexion-Speaker feesJanssen-Speaker fees

    Editorial Boards:

    1. J of Neurology-Editorial BoardFrontiers in Neurology-Editorial BoardJ of the Neurological Sciences-Editorial BoardNeuroimmunology Reports-Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. 1. Up To Date: i). Internuclear ophthalmoparesisii). Multiple Sclerosis: Symptom management2) Cambridge University PressOptical Coherence Tomography in Neurological Diseases

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. GenzymeNovartisAlexionJanssen

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Steven Galetta, MD,
    4. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. z

    Editorial Boards:

    1. (1) Neurology, Editorial Board;(2) Journal of Neuro-ophthalmology, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Laura J. Balcer, MD,
    5. Scientific Advisory Boards:

    1. Editor in Chief, Journal of Neuro-Ophthalmology, receive payments from the North American Neuro-Ophthalmology Society

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. Journal of Neuro-Ophthalmology, Editor-in-Chief, 2019-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Teresa C. Frohman, MPAS, PA-C,
    6. Scientific Advisory Boards:

    1. spouse:Genzyme, Alexion, Novartis, JANSSEN- speaking and consulting

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Spouse: Genzyme, Alexion, Novartis

    Editorial Boards:

    1. self and spouse:Editor Neurology ReportsContributor: Up To DateNMSS Fellows Webinar Case Conference Proceedings

    Patents:

    1. NONE

    Publishing Royalties:

    1. Self: Up-To-DateSpouse: Up-To-Date

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Spouse: Genzyme, Alexion, Novartis, Janssen

    Speakers' Bureaus:

    1. Spouse:Genzyme, Alexion, Novartis, Janssen

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Robert P. Lisak, MD,
    7. Scientific Advisory Boards:

    1. 1) Advisory Board Commercial: Argenx, Mallinckrodt, Takeda, Alivant, ANI, MedDay, Horizon 2) Advisory Board non-profit: National Multiple Sclerosis Society, Michigan Chapter, Clinical Advisory Committee; Myasthenia GravisFoundation of America, Clinical Advisory Committee;Guillain-Barre Syndrome/CIDP Foundation, International,Global Medical Advisory Commmittee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. Section Editor for Neuroimmunology, ClinicalNeuropharmacology, 2005-present; Editorial Board,Immunology Research, 1986-2021; Neuroimmunology Reports 2020-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. International Neurology: A Clinical Approach, Blackwell,Oxford, 2009; 2017 (2nd edition)Neuroimmunology, Oxford University Press, 2019

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1)GLG Consulting; Insight Consulting; Alpha SitesConsulting; Argenx; Clearview Consulting, Guidepoint Consulting; Jupiter Consulting; Dedham, Triangle Insights, Horizon Pharmaceuticals, ALI, Alivar,Takeda, COUR (Data Safety Monitoring Board) and ACTHar Gel, Takeda consulting on autoimmune neurologic disorders, Janssen consulting on S1P receptor modulators

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Health Advisory Committee; National MultipleSclerosis Society, Michigan Chapter, Board of Governors;Research Grants Committee and Centers of ExcellenceCommittee of the Medical Advisory Committee of theGBS/CIDP Foundation, International; Grants Committee ofthe Myasthenia Gravis Foundation of America ended-2020

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Alexion; Genentech, Novartis,Medimmune; Chugai, UCB/Ra Pharmaceuticals, Argenx, Takeda paid to Wayne State University for my participation in clinical trialsMedDay as Chair of Adjudication Committee for study ofbiotin in progressive forms of MS

    Research Support, Government Entities:

    1. NINDS; 1R21NS118227-01; PI; 7/15/2020-06/30/2023

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Scott D. Newsome, DO,
    8. Scientific Advisory Boards:

    1. Biogen Idec, scientific advisory boardGenentech, scientific advisory boardEMD Serono, scientific advisory boardBristol Myers Squibb, scientific advisory boardGreenwich Biosciences, scientific advisory boardNovartis, scientific advisory boardHorizon Therapeutics, scientific advisory boardmedDay Pharmaceuticals, clinical adjudication committee member for a clinical trial

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Autobahn

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. study lead PI for a Roche clinical trial

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Idec; research support payed directly to my institution and not relevant to the submitted manuscriptGenentech; research support payed directly to my institution and not relevant to the submitted manuscriptRoche; research support payed directly to my institution and not relevant to the submitted manuscript

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis SocietyDepartment of DefensePatient Centered Outcomes Research InstituteThe Stiff Person Syndrome Research Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Jennifer S. Graves, MD, PhD, MAS,
    9. Scientific Advisory Boards:

    1. Novartis, Genentech, Bayer

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. Assistant editor for Neurology 2020-2021Associate editor for ACTN 2019-2022

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Octave2) Biogen3) EMD Serono4) Sanofi

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) National MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Scott S. Zamvil, MD, PhD and
    10. Scientific Advisory Boards:

    1. Dr. Zamvil has received honoraria for serving on Data Safety Monitoring Boards for MS trials conducted by Opexa, BioMS, Teva Pharmaceuticals, Inc. and Eli Lilly and Co. Foundation.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Biogen - Speaker honoraria and advisory board meetings(2) Teva - Speaker honoraria and advisory board meetings(3) Alexion - Speaker honoraria and advisory board meetings(4) Novartis - Speaker honoraria and advisory board meetings(5) Horizon - Speaker honoraria and advisory board meetings

    Editorial Boards:

    1. (1) Neurology, Neuroimmunology and Neuroinflammation,Deputy Editor, 2014-present

    Patents:

    1. "Aquaporin-4 peptides and methods for using same"(SF2010-074; USF-461PRV (pending). The applicationdescribes the discovery of aquaporin-4 T cell determinantsin neuromyelitis optica patients and the use forantigen-specific tolerance.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. SSZ has served as a consultant to Biogen Idec, Teva Neuroscience, EMD-Serono, Genzyme, Novartis, Genentech/Roche, Horizon and Alexion.

    Speakers' Bureaus:

    1. Advanced Health Media, 2009-presentBiogen, 2009-presentAlexion, 2019-presentViela Bio, 2020Horizon, 2021-present

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen - speaker and advisory board meetings(2) Teva - speaker and advisory board meetings(3) Genentech - advisory board meeting(4) Novartis - advisory board meetings(5) Genzyme - advisory board meetings(6) Alexion - advisory board meeting(7) Horizon - advisory board meetings

    Research Support, Government Entities:

    1. NIH RO1 AI131624-O1A1NIH R21 NS10815990-01

    Research Support, Academic Entities:

    1. NMSS RG 1701-26628NMSS RG 1801-29861

    Research Support, Foundations and Societies:

    1. Alexander M. and June L. Maisin Foundation, PI

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Lilyana Amezcua, MD, MS
    11. Scientific Advisory Boards:

    1. 1) Genentech, 2) EMD Serono

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Genentech, Biogen Idec, EMD Serono, Sanofi/Genzyme

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1)Biogen Idec, 2)Novartis, 3)Genentech, 4)EMD Serono,

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Genentech, Sanofi

    Research Support, Government Entities:

    1. 1) NIH NINDS 1R01NS096212‐01 , Co-PI, 5 years 2) NIN NINDS 1R01NS123398-01, PI, 5 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) National Multiple Sclerosis Society NMSS 2)Race to Erase MS3) Bristol Myers Squibb Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (B.H., L.A.), University of Southern California (USC), Keck School of Medicine; Distinguished Senior Fellows (Sabbatical) Neuroimmunology Laboratory of Professor Lawrence Steinman (E.M.F., T.C.F.), Stanford University School of Medicine, Palo Alto, CA; Departments of Neurology (S.G., L.J.B.), Population Health (L.J.B.) and Ophthalmology (L.J.B., S.G.), New York University Grossman School of Medicine; Department of Neurology (R.P.L.), Wayne State University, Detroit MI; Department of Neurology (S.D.N.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neurosciences (J.S.G.), University of California, San Diego; and Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco.
  1. Correspondence
    Dr. Zamvil zamvil{at}ucsf.neuroimmunol.org
View Full Text

Article usage

Article usage: December 2022 to April 2023

AbstractFullPdfSource
Dec 202212901239Highwire
Jan 202326336150Highwire
Feb 20231723174Highwire
Mar 202312495127Highwire
Apr 20231216955Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me